Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Srinivas Nalamachu

Physical Medicine & Rehabilitation Overland Park, KS Medical Doctor

NPI 1497716914 CMS profile 158026

7100 College Blvd, Overland Park, KS 66210

Open in the dashboard

General payments

$344,296

227 records reported · program years 2019–2025

Research payments

$17,224

Paid to them · 9 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$351,371 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Srinivas Nalamachu of Overland Park, KS is reported in the CMS Open Payments database as having received $344,296 across 227 general payments and $17,224 in research payments paid to them. Separately, studies naming them as principal investigator received $351,371 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $168,539 54
2024 General $100,366 25
2023 General $50,533 20
2022 General $135 2
2021 General $7,168 20
2021 Research $11,800 3
2020 General $2,125 34
2020 Research $2,960 3
2019 General $15,430 72
2019 Research $2,464 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Srinivas Nalamachu
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Srinivas Nalamachu were reported at $168,539. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Srinivas Nalamachu Physical Medicine & Rehabilitation median Middle half National median
2019 $15,430 $133 $45–$390 $163
2020 $2,125 $88 $29–$272 $114
2021 $7,168 $116 $33–$360 $132
2022 $135 $123 $40–$378 $149
2023 $50,533 $131 $43–$396 $160
2024 $100,366 $141 $45–$409 $164
2025 $168,539 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Scilex Pharmaceuticals Inc. $312,018 78 payments
  2. Daiichi Sankyo Inc. $12,515 12 payments
  3. Tonix Pharmaceuticals, Inc. $5,450 5 payments
  4. Amgen Inc. $3,336 5 payments
  5. RedHill Biopharma Inc. $2,617 4 payments
  6. Pfizer Inc. $1,664 18 payments
  7. Biodelivery Sciences International, Inc. $1,538 4 payments
  8. Shionogi Inc $1,438 2 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $975 16 payments
  10. Vertex Pharmaceuticals Incorporated $375 1 payment
  11. Other $2,368 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $297,860 52 payments
  2. Travel and Lodging $19,321 22 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,101 10 payments
  4. Food and Beverage $5,734 138 payments
  5. Honoraria $4,274 3 payments
  6. Education $5 2 payments
Products named General payments · program years 2019–2025
  1. ZTLido $244,726 55 payments
  2. GLOPERBA $190,980 28 payments
  3. ELYXYB - CELECOXIB $150,739 26 payments
  4. ELYXYB $13,275 2 payments
  5. Morphabond ER $12,515 12 payments
  6. TONMYA $5,277 3 payments
  7. AIMOVIG $3,411 10 payments
  8. Movantik $2,617 4 payments
  9. BELBUCA $1,527 3 payments
  10. Symproic $1,438 2 payments
  11. Other $3,620 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Nevro Corp. $11,800 3 payments
  2. Pfizer Inc. $2,960 3 payments
  3. Novartis Pharmaceuticals Corporation $2,464 3 payments

Records

236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record